http___bg.gsk.com_bg-bg__D0_BE_D1_82_D0_B3_D0_BE_D0_B2_D0_BE_D1_80_D0_BD_D0_BE_D1_81_D1_82__D0_B0_D0_BD_D0_B3_D0_B0_D0_B6_D0_B8_D1_80_D0_B0_D0_BD_D0_B5-_D0_BD_D0_B0-_D0_BC_D0_B5_D0_B4_D0_B8_D1_86_D0_B8_D0_BD_D1_81_D0_BA_D0_B8-_D1_81_D0_BF_D0_B5_D1_86_D0_B8_D0_B0_D0_BB_D0_B8_D1_81_D1_82_D0_B8-_D0_BD_D0_B0_D1_88_D0_B8_D1_8F_D1_82-_D0_BF_D0_BE_D0_B4_D1_85_D0_BE_D0_B4__2.xml
1.1 2.1 2.2 3.1 4.1 4.2 4.3 5.1 6.1 6.2 6.3 6.4 6.5 6.6 7.1 8.1 8.2 8.3 9.1 9.2 9.3 10.1
Ангажиране на медицински специалисти (нашият подход) GSK България oповестява информация за трансфери на стойност направени към медицински специалисти и здравни организации, в съответствие с изискванията за прозрачност на кодекса за оповестяване на Европейската федерация на фармацевтичните индустрии и асоциации (EFPIA). Вярваме, че тези данни ще създадат по-добро разбиране за начина, по който работим с медицински специалисти и здравни организации и ще повишат доверието в работата ни с тях, за да предоставим подобрено здравеопазване в най-добрия интерес на пациентите. Оповестяване на плащания извършвани към медицински специалисти в България През последните години GSK поставя предизвикателство пред традиционния търговски модел на фармацевтичните компании, чрез водещи в отрасъла подобрения в начина на правене на бизнес. Нашите подобрения имат за цел да отговорят на нарастващото очакване на обществото за прозрачност в действията на организации и лица. Това включва взаимоотношенията ни с медицинските специалисти (МС) или здравните организации (ЗО), така че всички тези взаимодействия да се поддържат в почтеност и прозрачност. Ние напълно подкрепяме Кодекса на Европейската федерация на фармацевтичните индустрии и асоциации (EFPIA) за разкриването на индивидуалните трансфери на стойност от фармацевтични компании към здравни специалисти и здравни организации. Считано от 01.01.2016 г. GSK преустанови плащания към медицински специалисти, които говорят за нашите лекарства с рецепта или ваксини, включително пред лица, които могат да предписват или да влияят върху предписването. От януари 2016 г. GSK престава да осигурява и финансова подкрепа директно на отделните медицински специалисти за участие в медицински конгреси. Тези промени изпреварват текущите кодекси в отрасъла и следователно изпреварват и другите в индустрията. Продължаваме да работим с медицинските специалисти за непромоционални дейности, като например клинични проучвания. Съгласно кодекса, и до 30.06.2016 г., фирмите членуващи в EFPIA в цяла Европа, включително и GSK, се ангажират да публикуват индивидуалните трансфери на стойност направени през 2015 г., към МС и ЗО във връзка с лекарствата по лекарско предписание за всяко лице поотделно (като групирането е само по изключение). Оповестяването включва, например, спонсорство за пътуване и регистрационни такси за участие в медицински конгреси, консултантски хонорари на МС за изнасяне на лекции или за водене на заседания, както и спонсорства и дарения към ЗО. Трансфери на стойност към МС и ЗО за дейности свързани с научноизследователска и развойна дейност ще се оповестяват като обобщено число. Оповестяването, което правим през месец юни 2016 г. съгласно кодекса на EFPIA се отнася за 2015 г., преди GSK да е преустановила плащанията към лекторите-медицински специалисти. Вярваме, че това оповестяване ще допринесе за създаването на по-добро разбиране за начина, по който фармацевтичната индустрия работи с МС и ЗО. Като се имат предвид мерките, които GSK е въвела, ние се стремим да повишим доверието в медицинската професия и разбирането за това как и защо работим с тях за устойчиво подобряване на здравеопазването и в най-добрия интерес на пациентите. Повече информация за нашия подход към кодекса на EFPIA, за това как водим подобренията на практиките в отрасъла, както и значението на нашите партньорства МС и ЗО може да се открие по-долу и е изложена в по-големи подробности тук. Нашето оповестяване за България може да се види тук.
1.1 2.1 2.2 3.1 4.1 5.1 6.1 7.1 8.1 9.1 10.1 11.1 11.2 12.1 13.1 13.2 14.1 15.1 15.2 16.1 17.1 18.1 18.2 18.3 19.1 19.2 20.1 21.1 22.1 22.2 23.1 25.1 26.1 28.1 29.1 31.1 32.1 34.1 35.1 36.1 36.2 37.1 38.1 38.2 39.1 40.1 40.2 41.1 42.1 43.1 44.1 45.1 46.1 47.1 48.1 50.1 51.1 53.1 54.1 56.1 57.1 59.1 60.1 61.1 61.2 62.1 63.1 63.2 64.1 65.1 66.1 67.1 68.1 70.1 71.1 73.1 74.1 76.1 77.1 79.1 80.1
Engaging with healthcare professionals As a healthcare company, we regularly work with healthcare professionals. From collaborating on clinical trials providing high quality, balanced information about our medicines and vaccines, in all of our interactions we aim to be transparent about our work, operate with integrity, and always put the interests of patients first. - Interactions with prescribers - Collaborating on clinical trials and research - Disclosure of payments made to HCPs In all of our interactions with healthcare professionals, our priority is to be transparent about our work, operate with integrity, and always put the interests of patients first. Pharmaceutical companies have an important role to play in providing healthcare professionals (HCPs) with accurate, high quality information about prescription medication and vaccines. This relationship is fundamental to the progress of medical science and to help meet patient and public health needs We believe this relationship is fundamental to the progress of medical science and to help meet patient and public health needs. At the end of 2013 we announced three industry leading changes to reform the way we interact with HCPs At the end of 2013 we announced three industry leading changes to the way we interact with HCPs. Since January 2016 all of these changes are now in place globally. Firstly, we have removed sales target linked incentives for our sales professionals: - From January 2015, GSK sales representatives are no longer rewarded based on individual sales targets. We will continue to invest in training our representatives so they have the knowledge and skills to provide HCPs with information and they will be rewarded for the quality of their interaction with HCPs. Secondly, we will continue to support medical education in new and different ways: - We continue to believe the industry plays a valuable role in supporting medical education to provide HCPs with information on disease, diagnosis and treatment. We will provide grants to independent organisations that deliver medical education and have no influence over content or who is to be trained. - We remain open to supporting HCPs to attend scientific congresses, but only through funding to third parties, so that GSK is not directly involved in decisions relating to the selection on HCPs. Thirdly, we have stopped direct payments to HCPs to speak on our behalf: - To help address any concerns about undue influence on prescriber behaviour and to introduce more transparency into our marketing and educational efforts, we have stopped payments to HCPs to speak on GSK’s behalf about our prescription medicines and vaccines. Instead, we’re developing new digital, personal and real-time applications to improve our delivery of information to HCPs. The expert medical doctors we have within GSK will have more time to talk with and answer questions about our medicines with their external peers. HCPs will remain valuable partners for GSK, and we will continue to pay HCPs for non-promotional activities that we could not do without them. These include: - Conducting GSK-sponsored clinical research - Advisory activities and market research which provide us with essential insights on specific diseases and patient care We are committed to publically disclosing payments we do make to healthcare professionals. Find out more by using the tabs above. Find out more Vaccines travel sponsorship Support for travel sponsorship for global/international independent medical education activities or scientific congresses Vaccines independent medical education GSK Vaccines: support for independent medical education Respiratory independent medical education Support for severe asthma independent medical education Our behaviour We are changing the way we work to further embed our values in everything we do, including the way we research, develop, sell and market our products Healthcare professionals (HCPs) help us identify potential volunteers for clinical trials, administer the investigational medicine or vaccine to patients, and monitor the results. This unique medical insight and knowledge is vital to the development of new treatments. At the core of these relationships is a shared concern for improving the health of patients, based on our values of transparency, respect, integrity and patient focus. All HCPs who work with us on clinical trials have contracts and are paid for their work on these clinical trials. This payment covers their time, plus the cost of investigations they may need to carry out regarding the suitability of a patient and the effectiveness of the treatment. Our policies We have strict policies governing all our work with HCPs. These state that: - all clinical trial investigators are selected solely on their qualifications to conduct good quality clinical research - their history of using or not using GSK products must not be taken into account when deciding whether to include them as clinical trial investigators - no payments are offered or made to influence their judgement on whether to enrol or maintain a patient in a clinical study - gifts are not permissible to healthcare professionals involved in research projects for GSK - all payments to HCPs must be governed by contracts - any payment must reflect fair market value for the work performed and the services provided. We also have a commitment to publicly disclose the research payments that are made to healthcare professionals and to their institutions for conducting clinical research. Find out more about us Our behaviour commitments We aim to ensure our employees and the third parties we work with act according to our values – patient focus, integrity, respect for people and transparency. Our behaviour We are changing the way we work to further embed our values in everything we do, including the way we research, develop, sell and market our products Our people Learn how we create an inspiring and supportive work environment that encourages employees to develop capabilities and achieve their best Our planet To ensure we deliver high quality products to patients and consumers, we must protect the natural resources we need to make them today From 1st January 2016, we stopped making payments to healthcare professionals (HCPs) to speak about our prescription medicines and vaccines to audiences who can prescribe or who can influence prescribing. We have also ended the practice of providing direct financial support for individual HCPs to attend medical conferences. We acknowledge the importance of increased transparency and of putting the patient at the centre of every decision we take. In many countries, we already publish payments made to HCPs. For example, in Australia, France, Netherlands, Portugal, Slovakia, Japan, the UK and the USA, we publish payments in line with local government regulation or industry association Codes. We will continue to support and work towards increased transparency in other countries as industry associations or governments establish specific guidelines for disclosure - for example, through the European Federation of Pharmaceutical Industry Association (EFPIA) Disclosure Code. We also continue to work towards publishing global figures at an aggregate level for payments to HCPs, for activities such as advisory services and clinical research. Find out more about our payments to HCPs in the USA, Europe and the rest of the world via the pages within this section. Find out our approach towards the EFPIA Disclosure Code and how we are leading the industry in modernising our commercial business model. Disclosure by region USA We were one of the first pharmaceutical companies in the USA to voluntarily disclose information about our work with physicians Europe We fully support the EFPIA's Code on the disclosure of individual transfers of value from pharmaceutical companies to healthcare professionals and healthcare organisations Rest of the world We continue to support and work towards transparency as industry associations or governments establish specific guidelines for disclosure around the world Our behaviour We are changing the way we work to further embed our values in everything we do, including the way we research, develop, sell and market our products